Get told when this changes
Enter your email and you will hear from this site only when something on it actually changes.
One email per real change. No tracking pixels, no list rental, one-click unsubscribe.
What you will get
- A regulatory decision — an approval, a rejection, a delay, or a new filing accepted.
- A program changing phase, in either direction.
- A trial reading out, opening, or being terminated.
- A program changing hands, as cleminorexton did when Eli Lilly acquired Centessa.
Every alert says what changed, on what date, and links to the primary source it came from. That is the whole format.
What you will not get
- A weekly digest of nothing in particular.
- Anything sold to you. There is nothing here to buy, and this list is not for rent or sale.
- Tracking pixels or open-rate surveillance.
- Investment advice. This site reports what sponsors and regulators have said and does not tell anyone what to do about it.
Nearest event
oveporexton — FDA decision window, Q3 2026. NDA accepted with Priority Review on 10 Feb 2026. The FDA set a PDUFA target in the third quarter of 2026 without naming a day. As of Takeda's Q1 FY2026 earnings release on 30 Jul 2026, the US application remained under review, with launch preparations underway for the second half of 2026.